GTS-21, a Nicotinic Agonist, Protects against Neocortical Neuronal Cell Loss Induced by the Nucleus Basalis Magnocellularis Lesion in Rats

The Japanese Journal of Pharmacology

Jyunji Yamamoto²  Nobuo Kasahara²  Hidekazu Miyake²  Hiroshi Watanabe¹  Masato Nanri² 

[1] Department of Pharmacology, Research Institute for Wakan-Yaku (Oriental Medicines), Toyama Medical and Pharmaceutical University;Department of Pharmacology, Taiho Pharmaceutical Co., Ltd.

关键词: GTS-21;    Nicotinic agonist;    Neuronal cell loss;   

DOI  :  10.1254/jjp.74.285

学科分类：药理学

来源: Nihon Yakuri Gakkai Henshuubu / Japanese Pharmacological Society

【 摘 要 】

References(15)Cited-By(21)Effect of subchronically administered GTS-21 [3-(2, 4-dimethoxybenzylidene)-anabaseine dihydrochloride], a selective nicotinic agonist, on neuronal cell loss caused by nucleus basalis magnocellularis (nBM)lesion was studied in rats. After 2 weeks of bilateral nBM excitotoxic lesion, GTS-21 was orally administered once daily for 20 weeks. Neuronal cell loss was observed in layers 11-111 of the parietal cortex in the lesioned control rats. GTS-21 significantly attenuated the neuron loss in these layers. These results suggest that GTS-21 exhibits a protective action against the neuronal cell death in the parietal cortex and may have a beneficial effect on neurodegenerative disorders such as an Alzheimer-type disease.

【 授权许可】

Unknown